- Revenues were $212,000, up 685% over the third quarter of 2011
- Continued patient enrollment for RenalGuard U.S. pivotal trial at 9 trial sites
- Made progress in Latin America (excluding Brazil where regulatory approval to market has already been obtained) on securing regulatory approvals for RenalGuard marketing on a country-by-country basis
- Continued to broaden awareness of Contrast-Induced Nephropathy (CIN) with presence at key medical conferences including Latin American Society of Interventional Cardiology 2012 (SOLACI) and Transcatheter Cardiovascular Therapeutics (TCT) 2012
- Investigators presented their published research on the ability of RenalGuard potentially to reduce the toxic effects of contrast media on the kidneys
- Secured $1.0 million in financing with another $1.0 million still available based upon achievement of milestones
PLC Systems Reports Third Quarter Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.